Company intelligence / Profile preview

KYM Biosciences

Ownership: Private
Development stage: Phase 1

Overview

KYM Biosciences’ lead program, CMG901, an antibody-drug conjugate targeting Claudin 18.2 for gastric and related cancers, showed a favorable safety profile and encouraging anti-tumor efficacy in Phase I trials. In a subset of patients with Claudin 18.2-positive gastric/GEJ cancer treated with CMG901, the objective response rate was reported at up to 100% in certain dose cohorts. The program received Breakthrough Therapy Designation from Chinese regulators for advanced gastric cancer.

Therapeutic areas: Oncology
Modalities: Antibody-drug conjugate
Industry: Biotech

Drug pipeline

3 assets

CMG901

Phase 1

Indications: Gastric cancer, Solid tumors

2 more assets in the full pipeline.

Request access →

Partnerships

AstraZeneca (global exclusive licensee for CMG901)

Beyond the preview

Go deeper on KYM Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KYM Biosciences.

Explore the full profile